THE World Health Organization (WHO) recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. All-oral regimens simplify DR-TB treatment for children and caregivers by eliminating the use of injectable drugs that can cause deafness and by making the treatment regimens shorter, less toxic, and more effective. Health Reporter However, adopting these new recommendations in high TB burden countries requires access to the paediatric formulations of bedaquiline (produced by Johnson & Johnson) and delamanid…
Read MorePaediatric TB Medications Still Out Of Reach For Many
